<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li L</submitter><funding>Dongguan Science and Technology of Social Development Program</funding><funding>Science and Technology Program of Guangzhou</funding><funding>Natural Science Foundation of Guangdong Province</funding><pagination>0364</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11077293</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7</volume><pubmed_abstract>The intestinal and intratumoral microbiota are closely associated with tumor progression and response to antitumor treatments. The antibacterial or tumor microenvironment (TME)-modulating approaches have been shown to markedly improve antitumor efficacy, strategies focused on normalizing the microbial environment are rarely reported. Here, we reported the development of an orally administered inulin-based hydrogel with colon-targeting and retention effects, containing hollow MnO&lt;sub>2&lt;/sub> nanocarrier loaded with the chemotherapeutic drug Oxa (Oxa@HMI). On the one hand, beneficial bacteria in the colon specifically metabolized Oxa@HMI, resulting in the degradation of inulin and the generation of short-chain fatty acids (SCFAs). These SCFAs play a crucial role in modulating microbiota and stimulating immune responses. On the other hand, the hydrogel matrix underwent colon microbiota-specific degradation, enabling the targeted release of Oxa and production of reactive oxygen species in the acidic TME. In this study, we have established, for the first time, a microbiota-targeted drug delivery system Oxa@HMI that exhibited high efficiency in colorectal cancer targeting and colon retention. Oxa@HMI promoted chemotherapy efficiency and activated antitumor immune responses by intervening in the microbial environment within the tumor tissue, providing a crucial clinical approach for the treatment of colorectal cancer that susceptible to microbial invasion.</pubmed_abstract><journal>Research (Washington, D.C.)</journal><pubmed_title>Orally Administrated Hydrogel Harnessing Intratumoral Microbiome and Microbiota-Related Immune Responses for Potentiated Colorectal Cancer Treatment.</pubmed_title><pmcid>PMC11077293</pmcid><funding_grant_id>20211800905282</funding_grant_id><funding_grant_id>202201011130280065</funding_grant_id><funding_grant_id>2023A1515030291</funding_grant_id><pubmed_authors>Wang M</pubmed_authors><pubmed_authors>He S</pubmed_authors><pubmed_authors>Zou Z</pubmed_authors><pubmed_authors>Yu M</pubmed_authors><pubmed_authors>Liao B</pubmed_authors><pubmed_authors>Shu Z</pubmed_authors><pubmed_authors>Lin H</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Hu B</pubmed_authors><pubmed_authors>Lan X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Orally Administrated Hydrogel Harnessing Intratumoral Microbiome and Microbiota-Related Immune Responses for Potentiated Colorectal Cancer Treatment.</name><description>The intestinal and intratumoral microbiota are closely associated with tumor progression and response to antitumor treatments. The antibacterial or tumor microenvironment (TME)-modulating approaches have been shown to markedly improve antitumor efficacy, strategies focused on normalizing the microbial environment are rarely reported. Here, we reported the development of an orally administered inulin-based hydrogel with colon-targeting and retention effects, containing hollow MnO&lt;sub>2&lt;/sub> nanocarrier loaded with the chemotherapeutic drug Oxa (Oxa@HMI). On the one hand, beneficial bacteria in the colon specifically metabolized Oxa@HMI, resulting in the degradation of inulin and the generation of short-chain fatty acids (SCFAs). These SCFAs play a crucial role in modulating microbiota and stimulating immune responses. On the other hand, the hydrogel matrix underwent colon microbiota-specific degradation, enabling the targeted release of Oxa and production of reactive oxygen species in the acidic TME. In this study, we have established, for the first time, a microbiota-targeted drug delivery system Oxa@HMI that exhibited high efficiency in colorectal cancer targeting and colon retention. Oxa@HMI promoted chemotherapy efficiency and activated antitumor immune responses by intervening in the microbial environment within the tumor tissue, providing a crucial clinical approach for the treatment of colorectal cancer that susceptible to microbial invasion.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-08T06:02:51.241Z</modification><creation>2026-06-08T03:14:20.13Z</creation></dates><accession>S-EPMC11077293</accession><cross_references><pubmed>38721274</pubmed><doi>10.34133/research.0364</doi></cross_references></HashMap>